Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two potent synthetic opioid analgesics, fentanyl and remifentanil. Both drugs act as agonists at the mu-opioid receptor, providing strong analgesic effects and are commonly used in anesthesia and critical care settings. Fentanyl is known for its rapid onset and relatively short duration of action compared to other opioids, but it can accumulate with prolonged use due to hepatic metabolism[7][8]. Remifentanil is distinguished by its ultra-short duration of action because it is rapidly metabolized by nonspecific blood and tissue esterases, resulting in a context-insensitive half-life of less than 10 minutes regardless of infusion duration[1][2][3][6]. The combination may be used to achieve rapid titration for varying levels of surgical stimuli or sedation requirements, offering flexibility in anesthetic management. Both agents share similar side effect profiles including respiratory depression, bradycardia, hypotension, and potential for dependence or abuse[2][7]. There are no unique brand names or fixed-dose products combining these two agents; their co-administration would be determined by clinical need.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fentanyl + remifentanil.